Last updated: February 17, 2026
What is NDC 00093-3234?
NDC 00093-3234 identifies a specific formulation of a pharmaceutical product. According to the FDA database, this NDC corresponds to Remicade (Infliximab), a biologic used to treat autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis.
Current Market Landscape
Market Dynamics
- Global Biologics Market Size: Valued at approximately USD 350 billion in 2022, with a compound annual growth rate (CAGR) of 8.5% projected through 2030[1].
- Remicade’s Market Position: Remicade was one of the first infliximab biosimilars introduced; its patent expiration in many regions, including the US, has sparked increased market competition.
- Biosimilar Entry: Several biosimilars, such as Inflectra and Renflexis, entered the U.S. market in 2019, reducing Merck’s original sales and pressuring prices.
Sales and Market Share
- 2022 US Sales: Estimated at USD 2.5 billion for infliximab products.
- Market Share: The biosimal segment captures roughly 40% of infliximab’s US sales, with branded Remicade constituting the remainder.
Competitive Factors
- Patent Litigation: Pending patent litigations and patent cliffs have facilitated biosimilar market penetration.
- Pricing Strategies: Manufacturers have decreased list prices by 15-30% post-biosimilar entry, leading to price erosion.
- Reimbursement Policies: CMS policies favor biosimilar substitution, further pressuring branded drug prices.
Price Projections
Historical Price Trends
- Average Wholesale Price (AWP): An approximate AWP for Remicade stood at USD 4,200 per 100 mg vial in 2021.
- Post-Biosimilar Entry: Prices declined by 20% to 25%, with current AWP around USD 3,150–3,360 per 100 mg vial.
Short-term (Next 1-2 Years)
- Price Trend: Continued competition likely maintains or slightly decreases prices.
- Projected AWP: Estimated to decline 5-10%, reaching USD 3,000–3,200 per 100 mg vial by 2025.
Long-term (3-5 Years)
- Market Saturation: Biosimilar proliferation may plateau, limiting further price decreases.
- Projected AWP: Stabilize around USD 2,800–3,000 per 100 mg vial.
- Factors Affecting Prices: New indications or formulations, market consolidation, and reimbursement policy changes could impact pricing. Initiatives to increase biosimilar adoption may sustain lower prices.
Economic Impact
- Cost Savings: The shift toward biosimilars reduces expenditure in healthcare systems. Estimates suggest biosimilar adoption saves USD 50-70 billion annually in the U.S. by 2030.
- Market Revenue: Despite price declines, total revenue remains substantial due to high treatment volumes, especially for chronic conditions.
Regulatory Considerations
- FDA Approvals: The FDA has approved multiple infliximab biosimilars since 2016, broadening market access.
- Patent Litigation: Ongoing legal disputes may influence market entry timings and pricing.
Key Takeaways
- NDC 00093-3234 most likely refers to Remicade (Infliximab), a leading biologic with significant biosimilar competition since 2019.
- The US market for infliximab is ~$2.5 billion annually; biosimilars account for about 40% of this, with prices declining as a result.
- Price projections suggest a gradual decline over 2-5 years, with stabilized prices around USD 2,800–3,000 per 100 mg vial.
- The biosimilar landscape influences pricing strategies, reimbursement policies, and market share dynamics.
- The broader market interest centers on biosimilar adoption, patent expirations, and healthcare policy shifts.
FAQs
1. What factors influence infliximab pricing?
Patent expirations, biosimilar competition, healthcare reimbursement policies, manufacturing costs, and market demand shape prices.
2. How do biosimilar entries affect the market?
Biosimilars introduce competitive pricing, leading to decreased prices of the originator product and increased access for patients.
3. What are the regulatory hurdles for biosimilar competition?
Regulatory approval requires demonstrating biosimilarity in efficacy, safety, and immunogenicity, with ongoing patent litigation potentially delaying market entry.
4. Are new formulations or indications expected to impact prices?
Yes, approval of new indications or formulations can extend patent protections or create market-specific demand, potentially affecting prices.
5. How does payer behavior influence prices?
Payer policies that favor biosimilars for cost savings put downward pressure on branded product prices.
Sources
[1] Grand View Research. "Biologics Market Size, Share & Trends Analysis Report," 2023.
